Elutia Inc Class A (ELUT)

Elutia's stock price has experienced volatility over the past six months (October 2025 - April 2026). In October 2025, the company announced the closing of its BioEnvelope business sale to Boston Scientific Corporation for $88 million and reported third-quarter 2025 financial results. In December 2025, the stock experienced a 28% price drop due to lackluster performance. In January 2026, Elutia reported preliminary fourth-quarter 2025 results, showing a 16% year-over-year revenue increase and a strengthened financial position. In March 2026, Elutia announced grants of inducement awards to new employees and presented at Sidoti's Small-Cap Virtual Investor Conference. As of April 2, 2026, the stock price was $1.17 per share, representing a decline of 59.79% from April 3, 2025.

There is no explicit information available regarding demand seasonality for Elutia, Inc.'s products and services.

Elutia, Inc. is a commercial-stage biotechnology company focused on developing and commercializing drug-eluting biomatrix products to enhance the compatibility between medical devices and patients. The company operates within the Healthcare sector, specifically in the Medical Devices and Biotechnology industries. Elutia's mission is to humanize medicine so patients can thrive without compromise. Elutia's product portfolio spans Women's Health and Cardiovascular segments, including EluPro, CanGaroo, SimpliDerm, Tyke, ProxiCor, and VasCure. The company is also developing NXT-41 and NXT-41x, next-generation biologic scaffolds combined with local antibiotic delivery.

Elutia, Inc. primarily operates and sells its products within the United States. The company's corporate headquarters are located in Gaithersburg, Maryland. Its processing, production, and distribution facility for implantable electronic device protection and cardiovascular products are in Roswell, Georgia. Elutia also maintains a research and development and corporate support center in Silver Spring, Maryland, and an additional administrative oversight and support location in San Diego, California. The company sources, manufactures, and distributes 100% of its products within the United States, and all product sales occur domestically.

Elutia's brand reputation in the past year appears to be positively influenced by its pioneering work in drug-eluting biomatrix technologies and successful product developments. The FDA clearance of EluPro as the first and only antibiotic-eluting biomatrix for CIEDs and neurostimulators is a significant achievement. The strong initial demand and physician adoption of EluPro, along with its successful navigation of hospital value analysis committees, further indicate a positive reception in the medical community.

Elutia, Inc. has a mixed ownership structure comprising institutional, insider, and retail investors. Institutional investors hold approximately 34.77% to 51.4% of the company's stock. Insiders own approximately 15.84% to 93.56% of the company's stock, with Highcape Capital LP being the largest individual shareholder. Retail investors hold approximately 0.00% to 43.51% of the stock.